Research progress onneoadjuvant therapy in stage IIIA-N2 non-small cell lung cancer

中华放射肿瘤学杂志 Pub Date : 2020-01-15 DOI:10.3760/CMA.J.ISSN.1004-4221.2020.01.014

Xin Sun, Y. Men, Z. Hui

引用次数: 0

Abstract

ⅢA-N2 NSCLC is a group of heterogeneous diseases. The optimal treatment modality remains controversial. How to choose suitable neoadjuvant treatment modalities including chemotherapy, radiotherapy, target therapy and immunotherapy remains unclear. In this article, research progress on neoadjuvant therapy of NSCLC was reviewed to evaluate the efficacy and safety for different modalities. Key words: Carcinoma, non-small cell lung/neoadjuvant therapy; Research progress

查看原文本刊更多论文

IIIA-N2期非小细胞肺癌新辅助治疗研究进展

ⅢA-N2型NSCLC是一组异质性疾病。最佳治疗方式仍然存在争议。如何选择合适的新辅助治疗方式，包括化疗、放疗、靶向治疗和免疫疗法，目前尚不清楚。本文综述了非小细胞肺癌新辅助治疗的研究进展，以评价不同方法的疗效和安全性。关键词：癌症、非小细胞肺癌/新辅助治疗；研究进展

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

中华放射肿瘤学杂志

自引率

0.00%

发文量

6375

期刊介绍： The Chinese Journal of Radiation Oncology is a national academic journal sponsored by the Chinese Medical Association. It was founded in 1992 and the title was written by Chen Minzhang, the former Minister of Health. Its predecessor was the Chinese Journal of Radiation Oncology, which was founded in 1987. The journal is an authoritative journal in the field of radiation oncology in my country. It focuses on clinical tumor radiotherapy, tumor radiation physics, tumor radiation biology, and thermal therapy. Its main readers are middle and senior clinical doctors and scientific researchers. It is now a monthly journal with a large 16-page format and 80 pages of text. For many years, it has adhered to the principle of combining theory with practice and combining improvement with popularization. It now has columns such as monographs, head and neck tumors (monographs), chest tumors (monographs), abdominal tumors (monographs), physics, technology, biology (monographs), reviews, and investigations and research.